Terzah Horton
Terzah Horton
Associate Professor of Pediatric Oncology, Baylor College of Medicine
Verified email at - Homepage
Cited by
Cited by
Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age
M Corral-Debrinski, T Horton, MT Lott, JM Shoffner, M Flint Beal, ...
Nature genetics 2 (4), 324-329, 1992
Marked changes in mitochondrial DNA deletion levels in Alzheimer brains
M Corral-Debrinski, T Horton, MT Lott, JM Shoffner, AC McKee, MF Beal, ...
Genomics 23 (2), 471-476, 1994
Mitochondrial DNA mutations in human degenerative diseases and aging
DC Wallace, JM Shoffner, I Trounce, MD Brown, SW Ballinger, ...
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1271 (1), 141-151, 1995
Novel mitochondrial DNA deletion found in a renal cell carcinoma
TM Horton, JA Petros, A Heddi, J Shoffner, AE Kaufman, SD Graham Jr, ...
Genes, Chromosomes and Cancer 15 (2), 95-101, 1996
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
KL Bride, TL Vincent, SY Im, R Aplenc, DM Barrett, WL Carroll, R Carson, ...
Blood, The Journal of the American Society of Hematology 131 (9), 995-999, 2018
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
TM Horton, A Gannavarapu, SM Blaney, DZ D’Argenio, SE Plon, SL Berg
Cancer chemotherapy and pharmacology 58, 13-23, 2006
The 10,400-and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor
LR Gooding, TS Ranheim, AE Tollefson, L Aquino, P Duerksen-Hughes, ...
Journal of virology 65 (8), 4114-4123, 1991
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study
TM Horton, D Pati, SE Plon, PA Thompson, LR Bomgaars, PC Adamson, ...
Clinical cancer research 13 (5), 1516-1522, 2007
The E1B 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells
LR Gooding, L Aquino, PJ Duerksen-Hughes, D Day, TM Horton, SP Yei, ...
Journal of virology 65 (6), 3083-3094, 1991
JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias
C Delgado-Martin, LK Meyer, BJ Huang, KA Shimano, MS Zinter, ...
Leukemia 31 (12), 2568-2576, 2017
Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients
TM Horton, BH Graham, M Corral-Debrinski, JM Shoffner, AE Kaufman, ...
Neurology 45 (10), 1879-1883, 1995
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015)
SM Blaney, M Bernstein, K Neville, J Ginsberg, B Kitchen, T Horton, ...
Journal of clinical oncology 22 (23), 4804-4809, 2004
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group
R Aplenc, S Meshinchi, L Sung, T Alonzo, J Choi, B Fisher, R Gerbing, ...
Haematologica 105 (7), 1879, 2020
Poly (ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O 6-methylguanine …
TM Horton, G Jenkins, D Pati, L Zhang, ME Dolan, A Ribes-Zamora, ...
Molecular cancer therapeutics 8 (8), 2232-2242, 2009
Adenovirus E3 14.7 K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis
TM Horton, TS Ranheim, L Aquino, DI Kusher, SK Saha, CF Ware, ...
Journal of virology 65 (5), 2629-2639, 1991
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4
CR Cruz, U Gerdemann, AM Leen, JA Shafer, S Ku, B Tzou, TM Horton, ...
Clinical Cancer Research 17 (22), 7058-7066, 2011
Bortezomib reinduction chemotherapy in high‐risk ALL in first relapse: a report from the Children's Oncology Group
TM Horton, JA Whitlock, X Lu, MM O'Brien, MJ Borowitz, M Devidas, ...
British journal of haematology 186 (2), 274-285, 2019
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre …
PD Cole, KM McCarten, Q Pei, M Spira, ML Metzger, RA Drachtman, ...
The Lancet Oncology 19 (9), 1229-1238, 2018
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)
JA Muscal, PA Thompson, TM Horton, AM Ingle, CH Ahern, RM McGovern, ...
Pediatric blood & cancer 60 (3), 390-395, 2013
Outcomes for children with gallbladder abnormalities and sickle cell disease
MN Suell, TM Horton, MK Dishop, DH Mahoney Jr, OO Olutoye, ...
The Journal of pediatrics 145 (5), 617-621, 2004
The system can't perform the operation now. Try again later.
Articles 1–20